Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DuPont Changing Labels For Antiseptic Products To Comply With FDA Warning

This article was originally published in The Tan Sheet

Executive Summary

DuPont plans by the end of June to comply with FDA's warning to change the labels for its RelyOn antiseptic spray and hand-wipe products that include disease claims not approved in a pending monograph for OTC health care antiseptics or in the topical antifungal drug products monograph

You may also be interested in...



FDA Budget Reaffirms Commitment To OTCs, Reduces Supplement Programs

FDA hopes to increase the number of over-the-counter drugs on the market as part of its long-term goal to provide consumers with safe, effective and affordable drugs, the agency states in its fiscal year 2007 budget request presentation

Antiseptic Products “Not Effective” In Reducing Skin Infection – FDA

No available evidence demonstrates that consumer antiseptic products reduce the risk of skin infection and such indications should not be included in the drug monograph, Office of Nonprescription Products reviewers say

Congress Likely To Legislate Monetary Penalty Authority In FTC Enforcement If SCOTUS Strikes It

White House, Democrat majority in Congress and likely next FTC chair support the agency wielding the authority, says advertising law attorney Holly Melton. Supreme Court, though, likely will rule in pending cases that a strict reading of an FTC regulation doesn’t grant monetary penalty authority.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel